The severity of side effects of talquetamab-tgvs and how to deal with them

Talquetamab, as a bispecific antibody drug, has shown potential efficacy in patients with relapsed or refractory multiple myeloma, but immune-related side effects may still occur during use. The most common adverse reactions include cytokine release syndrome (CRS), rash, fever, fatigue, and hematological abnormalities, such as a decrease in white blood cells or platelets. These side effects are usually mild to moderate in severity, but some patients may develop severe symptoms that require prompt intervention.

Cytokine release syndrome is one of the most concerning immune responses during Taquitumab treatment. Mild to moderate CRS is usually managed clinically through graded monitoring and symptomatic management, such as short-term pharmacological support, fluid management, and antipyretic and analgesic treatment. For hematological abnormalities, regular blood routine monitoring is crucial to promptly adjust the dose or temporarily discontinue the drug if neutropenia or anemia is found. Cutaneous and mucosal reactions may also occur but can be relieved with topical care and symptomatic medication.

The guideline emphasizes that the safety management of taquinutumab relies on early identification and timely intervention. Patients should receive a detailed physical assessment before treatment and be closely monitored during treatment, such as body temperature, rash, blood pressure, respiratory status, etc. Once moderate to severe symptoms occur, doctors can adjust the dose, delay medication, or use pretreatment drugs, including corticosteroids, antihistamines, and antipyretics, according to the situation, to reduce the risk of immune-related reactions.

Standardized side effect management can not only reduce the incidence of serious events but also ensure that patients continue to receive treatment, thereby maximizing the efficacy of Tacistumumab in relapsed or refractory multiple myeloma. With the accumulation of clinical experience and optimization of combination treatment strategies, the safety and accessibility of this drug are expected to be further improved, providing more patients with effective immunotherapy options.

Reference materials:https://www.talveyhcp.com/